Basic Study

Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source

Michelle L Boland, Denise Oró, Kirstine S Tølbøl, Sebastian T Thrane, Jens Christian Nielsen, Taylor S Cohen, David E Tabor, Fiona Fernandes, Andrey Tovchigrechko, Sanne S Veidal, Paul Warrener, Bret R Sellman, Jacob Jelsing, Michael Feigh, Niels Vrang, James L Trevaskis, Henrik H Hansen

Abstract

BACKGROUND

The trans-fat containing AMLN (amylin liver non-alcoholic steatohepatitis, NASH) diet has been extensively validated in C57BL/6J mice with or without the Lep<sup>ob</sup>/Lep<sup>ob</sup> (ob/ob) mutation in the leptin gene for reliably inducing metabolic and liver histopathological changes recapitulating hallmarks of NASH. Due to a recent ban on trans-fats as food additive, there is a marked need for developing a new diet capable of promoting a compatible level of disease in ob/ob and C57BL/6J mice.

AIM

To develop a biopsy-confirmed mouse model of NASH based on an obesogenic diet with trans-fat substituted by saturated fat.

METHODS

Male ob/ob mice were fed AMLN diet or a modified AMLN diet with trans-fat (Primex shortening) substituted by equivalent amounts of palm oil [Gubra amylin NASH, (GAN) diet] for 8, 12 and 16 wk. The Lep<sup>ob</sup>/Lep<sup>ob</sup> (ob/ob) mutation in the leptin gene for reliably inducing metabolic and liver histopathological changes recapitulating hallmarks of NASH. Due to a recent ban on trans-fats as food additive, there is a marked need for developing a new diet capable of promoting a compatible level of disease in ob/ob and C57BL/6J mice.

RESULTS

The GAN diet was more obesogenic compared to the AMLN diet and impaired glucose tolerance. Biopsy-confirmed steatosis, lobular inflammation, hepatic transcriptome changes were similar in ob/ob mice fed the GAN or AMLN diet. C57BL/6J mice developed a mild to severe steatohepatitis.
Lever-related complications have in recent years become widely recognized as among the most prevalent co-morbidities in obesity and diabetes. Non-alcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD), an umbrella term for a range of medical conditions with hepatic steatosis unrelated to significant alcohol consumption, use of steatogenic medication or hereditary disorders[1]. Notably, presence of obesity, dyslipidemia and type 2 diabetes constitutes the strongest risk factors for NASH[2-3], which has led to the concept that NASH represents the hepatic manifestation of the metabolic syndrome[4-5]. Liver biopsy represents the gold standard method for diagnosing and grading of NASH[4,5]. Liver-related complications have in recent years become widely recognized as among the most prevalent co-morbidities in obesity and diabetes. Non-alcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD), an umbrella term for a range of medical conditions with hepatic steatosis unrelated to significant alcohol consumption, use of steatogenic medication or hereditary disorders[1]. Notably, presence of obesity, dyslipidemia and type 2 diabetes constitutes the strongest risk factors for NASH[2-3], which has led to the concept that NASH represents the hepatic manifestation of the metabolic syndrome[4-5]. Liver biopsy represents the gold standard method for diagnosing and grading of NASH[4,5]. In NASH, lobular inflammation and liver cell damage (hepatocyte ballooning) are mandatory histopathological features in addition to steatosis[6]. Notably, the vast majority of patients with NAFLD across the disease spectrum is asymptomatic with the NAS system is now the most widely used scoring system in clinical trials for NASH.

INTRODUCTION

Liver-related complications have in recent years become widely recognized as among the most prevalent co-morbidities in obesity and diabetes. Non-alcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD), an umbrella term for a range of medical conditions with hepatic steatosis unrelated to significant alcohol consumption, use of steatogenic medication or hereditary disorders[1]. Notably, presence of obesity, dyslipidemia and type 2 diabetes constitutes the strongest risk factors for NASH[2-3], which has led to the concept that NASH represents the hepatic manifestation of the metabolic syndrome[4-5]. Liver biopsy represents the gold standard method for diagnosing and grading of NASH[4,5]. In NASH, lobular inflammation and liver cell damage (hepatocyte ballooning) are mandatory histopathological features in addition to steatosis[6]. Notably, the vast majority of patients with NAFLD across the disease spectrum is asymptomatic with the NAS system is now the most widely used scoring system in clinical trials for NASH.

The conspicuous clustering of obesity, diabetes and metabolic comorbidities in NASH patients underscores that overnutrition and dietary factors play an important role in the transition from mild NAFLD to manifest NASH. The pathogenesis of NASH is complex and multifactorial, implicating multiple parallel and converging signaling pathways. Current “multiple-hit” hypotheses consider several insults acting sequentially or together on a background of genetical predisposition to promote NAFLD and transition to NASH. Early pathogenic events are associated with hepatic triglyceride accumulation as result of excessive caloric intake, stimulation of hepatic de novo lipogenesis secondary to insulin resistance, and impaired fatty acid clearance. Increasing triglyceride levels in hepatocytes can lead to overproduction of moderate fibrotic NASH phenotype when fed the same diets.

CONCLUSION
Substitution of Primex with palm oil promotes a similar phenotype of biopsy-confirmed NASH in ob/ob and C57BL/6j mice, making GAN diet-induced obese mouse models suitable for characterizing novel NASH treatments.

Key words: Non-alcoholic steatohepatitis; High-fat diet; Mouse model; Histopathology; Fibrosis; Liver biopsy; Liver transcriptome

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The trans-fat containing amylin liver non-alcoholic steatohepatitis (NASH) (AMLN) diet has been extensively validated in mice for reliably inducing metabolic and liver histopathological changes recapitulating hallmarks of NASH. A recent ban on trans-fats as food additive prompted the development of a new diet with similar disease-inducing properties as the AMLN diet. Here, we introduce a trans-fat-free diet high in palm oil (Gubra amylin NASH, GAN diet) that promotes a highly similar phenotype of biopsy-confirmed fibrotic NASH in both ob/ob and C57BL/6j mice, highlighting the suitability of GAN diet-induced obese mouse models of biopsy-confirmed NASH for the characterization of novel drug therapies for NASH.

Citation: Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrener P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH. Towards a standard diet-induced and biopsy-confirmed NASH model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol 2019; 25(33): 4904-4920

URL: https://www.wjgnet.com/1007-9327/full/v25/i33/4904.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i33.4904
reactive lipid metabolites (lipotoxicity) that eventually override hepatic adaptive and regenerative mechanisms\textsuperscript{[11-13]}, triggering detrimental immune cell responses with downstream activation of resident fibrogenic myofibroblasts that produce and secrete collagens\textsuperscript{[13-15]}. In the event of continuing insufficient regenerative responses, progressive extracellular matrix deposition may result in excessive fibrotic liver damage and hepatocellular cancer.

The emergence of these theories has played an important role in the development of animal models of NASH with more reproducible and robust liver histopathology. Diet-induced obese (DIO) mice fed Western diets are attractive as they recapitulate the natural history of NASH\textsuperscript{[18]}. In addition, the human NAS system largely correlates with similar histopathologic lesions in these models\textsuperscript{[23]}, which makes obese mouse models of NASH increasingly employed in preclinical NASH research. Conventional obesogenic high-fat diets promote dyslipidemia, fatty liver, and mild-stage NASH without appreciable fibrosis in rodents\textsuperscript{[24]}. Hence, additional dietary stimuli (“hits”) are therefore applied to enhance the pro-fibrogenic properties of the high-fat diets employed in preclinical NASH research. Among the various dietary approaches, specific modifications in Western-type obesogenic diets have consistently been reported to promote fibrotic NASH in mice. Accordingly, C57BL/6J mice fed a high-fat/fructose diet supplemented with trans-fat and cholesterol (amylin liver NASH diet, i.e., AMLN diet\textsuperscript{[33]}) develop manifest NASH, characterized by steatosis, lobular inflammation and hepatocyte ballooning. Notably, a significant proportion of C57BL/6J mice fed the AMLN diet (AMLN DIO-NASH mice) develop mild to moderate fibrosis following \(\geq 26\) wk of feeding\textsuperscript{[18-23]}. The hepatopathology is similar, but accentuated, in leptin-deficient C57BL6J-Lep\textsuperscript{a/-}/Lep\textsuperscript{a/-} (ob/ob) mice fed the AMLN diet, demonstrating a fibrotic NASH phenotype after \(\geq 12\) wk of feeding\textsuperscript{[22,24-26]}. The two AMLN DIO models of NASH have been extensively characterized in pharmacology studies with employment of biopsy-confirmed histopathology for grading and staging of baseline liver pathology\textsuperscript{[25,26,27]}. As in the clinic, DIO mouse models of NASH have unpredictable onset of disease with varying rates of progression. Consequently, any given cohort of DIO mice may represent all stages of NAFLD following long-term high-fat feeding\textsuperscript{[18,22,26,27]}. This makes it imperative to control for inherently variable dynamics in NAFLD progression that could otherwise lead to misinterpretation of data obtained in longitudinal studies. Liver biopsy procedures have therefore recently been introduced to prevent bias and enable stringent within-subject analyses in both mice\textsuperscript{[18,22,26,27]} and rats\textsuperscript{[33]}

Addition of dietary trans-fats (also called trans-unsaturated fatty acids or trans fatty acids) has been reported to enhance the steatogenic and pro-fibrotic properties of obesogenic diets in mice, including the AMLN diet\textsuperscript{[22]} and variants thereof\textsuperscript{[23,24,26,27]}. The underlying molecular mechanisms are not fully understood, but trans-fats may likely sensitize to the hepatotoxic effects of high-fat/carbohydrate diets by increasing insulin resistance, hepatic lipogenesis and oxidative stress\textsuperscript{[24,25,26-28]}. A recent FDA ban on trans-fats as food additive\textsuperscript{[29]}, however, has prompted the development of a non-trans-fat Western diet capable of promoting metabolic and liver histopathological changes comparable to that afforded by the AMLN diet. The present study therefore aimed to develop and characterize a compatible biopsy-confirmed obese mouse model of NASH based on an isocaloric palmitic acid-enriched diet with a nutrient composition similar to the AMLN diet.

**MATERIALS AND METHODS**

**Animals**

Male ob/ob and C57BL/6J (C57) mice were from Jackson Laboratory (Bar Harbor, ME, United States) or Janvier Labs (Le Genest Saint Isle, France), arrived at 5-8 wk of age and housed in a controlled environment (12 h light/dark cycle, 21 ± 2 °C, humidity 50 ± 10%). Mice were stratified and randomized to individual diet groups according to baseline body weight and had ad libitum access to tap water and chow (2018 Teklad Rodent Diet, Envigo, Madison, WI, United States; Altromin 1324, Brogaarden, Hoersholm, Denmark), AMLN diet (40 kcal-% fat (of these 22% trans-fat and 26% saturated fatty acids by weight), 22% fructose, 10% sucrose, 2% cholesterol; D09100301, Research Diets, New Brunswick, NJ, United States)\textsuperscript{[22]} or Gubra amylin NASH diet [GAN diet; 40 kcal-% fat (of these 0% trans-fat and 46% saturated fatty acids by weight), 22% fructose, 10% sucrose, 2% cholesterol; D09100310, Research Diets]. Mice were fed chow, AMLN or GAN diet for 8, 12 or 16 wk (ob/ob) and 28 wk (C57BL/6J), respectively. The study was approved by The Institutional Animal Care and Use Committee at MedImmune (Gaitherburg, MD, United States) and The Danish Animal Experiments Inspectorate (license 2013-15-2934-00784) in accordance with...
internationally accepted principles for the use of laboratory animals.

**Body weight, body composition and liver fat mass**

Body weight was monitored weekly. Whole-body fat mass was analyzed at week 8, 12 and 16 of the feeding period by non-invasive EchoMRI scanning using EchoMRI-900 (EchoMRI, Houston, TX, United States). During the scanning procedure, mice were placed in a restrainer for 90-120 s.

**Intraperitoneal glucose tolerance test**

An intraperitoneal glucose tolerance test (ipGTT) was performed in week 7 of the feeding period. Animals were fasted for 4 h prior to administration of the glucose bolus (1.5 g/kg). Cages were changed at the time of fasting. At \( t = 0 \), C57 and \( ob/ob \) mice received a bolus of glucose by intraperitoneal injection (5 mL/kg). Blood samples were collected from the tail vein and blood glucose was measured at time points \( t = 0, 15, 30, 45, 60, 90 \) and 120 min after the glucose bolus. Mice were re-fed after the last blood sampling.

**Biochemical analyses**

Biochemical analyses were performed as reported previously\(^\text{[22,26]}\). Terminal plasma samples from fed animals were assayed for alanine aminotransferase (ALT), aspartate aminotransferase (AST), total triglycerides (TG) and total cholesterol. Total liver lipid mass was determined using a Bruker LF-90 minispec system (Bruker Biospin Corporation, Billerica, MA, United States) and expressed relative (%) to total liver weight.

**Liver biopsy**

A separate cohort of \( ob/ob \) mice were fed AMLN or GAN diet for 9 wk before a liver biopsy procedure was applied as described in detail previously\(^\text{[22]}\). On the surgery day, mice were anesthetized with isoflurane (2%-3%, in 100% oxygen), a small abdominal incision in the midline was made, and the left lateral lobe of the liver was exposed. A cone-shaped wedge of liver tissue (50-100 mg) was excised from the distal part of the lobe. The cut surface of the liver was closed by electrosurgical bipolar coagulation using an electrosurgical unit (ERBE VIO 100C, ERBE, Marietta, GA, United States). The liver was returned to the abdominal cavity, the abdominal wall was sutured and skin stapled. Carprofen (5 mg/kg, i.p.) was administered at the time of surgery and at post-operative day one and two. After the procedure, animals were single-housed and kept on the respective diet for a total period of 16 wk.

**Liver histology and digital image analysis**

Biopsy and terminal liver samples (both from the left lateral lobe) were fixed overnight in 4% paraformaldehyde. Liver tissue was paraffin-embedded and sectioned (3 µm thickness). Sections were stained with hematoxylin-eosin (HE, Dako, Glostrup, Denmark), Picro-Sirius red (Sigma-Aldrich, Broendby, Denmark), anti-galectin-3 (cat. 125402, Biolegend, San Diego, CA, United States), or anti-type I collagen (Col1α1; cat. 1310-01, Southern Biotech, Birmingham, AL, United States) using standard procedures\(^\text{[22,23]}\). The NAS and fibrosis staging system was applied to liver pre-biopsies and terminal samples for scoring of steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis outlined by Kleiner et al\(^\text{[10]}\). Quantitative histomorphometry was analyzed using digital imaging software (VIS Software, Visiopharm, Hørsholm, Denmark)\(^\text{[22,23]}\). Proportional (fractional) areas of liver fat (HE-staining), galectin-3 and Col1α1 were expressed relative to total sectional area. All histological assessments were performed by histologists blinded to the experimental groups.

**RNA sequencing**

Liver transcriptome analysis was performed by RNA sequencing on RNA extracts from terminal liver samples (15 mg fresh tissue), as described in detail elsewhere\(^\text{[22,23]}\). The RNA quantity was measured using Qubit (Thermo Scientific, Eugene, OR, United States). The RNA quality was determined using a bioanalyzer with RNA 6000 Nano kit (Agilent, Waldbronn, Germany). RNA sequence libraries were prepared with NeoPrep (Illumina, San Diego, CA, United States) using Illumina TruSeq stranded miRNA Library kit for NeoPrep (Illumina, San Diego, CA, United States) and sequenced on the NextSeq 500 (Illumina, San Diego, CA, United States) with NSQ 500 hi-Output KT v2 (75 CYS, Illumina, San Diego, CA, United States). Reads were aligned to the GRCh38 v84 Ensembl Mus musculus genome using STAR v.2.5.2a with default parameters\(^\text{[31]}\). Differential gene expression analysis was performed with DEseq237. Genes with a Benjamini and Hochberg adjusted \( P \leq 0.05 \) (5% false discovery rate, FDR) were regarded as statistically significantly regulated. The
Boland ML et al. Translational mouse model of non-alcoholic steatohepatitis

RESULTS

Metabolic changes in ob/ob mice fed GAN or AMLN diet for up to 16 wk
The temporal progression of metabolic deficits was determined in ob/ob mice fed the GAN (GAN ob/ob-NASH) or AMLN (AMLN ob/ob-NASH) diet for up to 16 wk. Body weight curves were significantly different in GAN and AMLN ob/ob-NASH mice (overall \( P < 0.001 \), two-way ANOVA). Compared to the AMLN diet, the GAN diet induced greater body weight gain in ob/ob mice from diet week 7 and onwards (Figure 1A). Relative body weight gain over the 16-week feeding period was 141.6 ± 2.9% (GAN ob/ob-NASH) and 125.2 ± 3.6% (AMLN ob/ob-NASH). GAN ob/ob mice displayed more pronounced increases in whole-body fat mass at all time points measured (Figure 1B). The GAN and AMLN diets promoted similar degree of hepatomegaly in ob/ob mice (Figure 1C). An ipGTT was performed in diet week 7 and demonstrated impaired glucose tolerance in GAN, but not AMLN, ob/ob-NASH mice compared to chow-fed C57 controls (Figure 1D and E). During the ipGTT, plasma insulin levels were equally elevated in GAN and AMLN ob/ob-NASH mice (Figure 1F). Plasma ALT and AST levels were significantly increased in GAN and AMLN ob/ob-NASH mice after 8 wk on the diet and did not change further during the 16-wk feeding period. The GAN and AMLN diets promoted a similar degree of hypercholesterolemia (diet week 8-16, \( P < 0.05 \)) in ob/ob mice with slightly reduced TG levels (diet week 16, \( P < 0.05 \)), as compared to chow-fed C57 mice (Table 1).

Terminal liver lipid levels in GAN and AMLN ob/ob-NASH mice were approximately 10-fold higher than that of age-matched C57 mice and were maximally elevated after 8 weeks of feeding (Table 1).

Gut microbiome changes in ob/ob mice fed GAN or AMLN diet for up to 16 wk
In addition to metabolic changes, the gut microbiome composition in GAN and AMLN ob/ob mice was characterized by bacterial 16S rDNA gene sequencing performed on serial fecal samples. The GAN and AMLN diets promoted similar taxonomic shifts compared to baseline (chow feeding). The structural modulation of the gut microbiota was largely manifest two weeks after the change to GAN or AMLN diet, being slightly more accentuated following 16 wk of feeding (Supplemental Figure 1). Compared to baseline, the changes in microbiome composition in GAN and AMLN ob/ob mice was mainly driven by increases in the relative abundance of Akkermansia, Bacteroides and Parasutterella with reciprocal decreases in Clostridiales and Porphyromonadaceae. Consistently lowered relative abundance of Lactobacillus was also observed in GAN ob/ob-NASH mice.

Biopsy-confirmed progression of liver histopathology in ob/ob mice fed GAN or AMLN diet for 16 wk
Liver histopathological changes in GAN ob/ob mice were assessed in ob/ob mice fed GAN or AMLN diet for 16 wk (n = 8-10 per group). A liver biopsy was sampled after 9 wk on the respective diet for within-subject analysis of disease progression. Representative histological stainings are shown in Figure 2A. Comparable changes in composite NAS and fibrosis scores from feeding week 9 to 16 were observed in GAN ob/ob and AMLN ob/ob mice (Figure 2B). At feeding week 9, GAN ob/ob and AMLN ob/ob mice showed mild-to-moderate fibrosis (F1-F2) with an equal distribution of mice progressing in fibrosis severity. A major proportion of GAN or AMLN diet fed ob/ob mice demonstrated moderate fibrosis after 16 weeks of feeding (Figure 2C). Individual pre-biopsy and terminal histopathological scores on steatosis, lobular inflammation and hepatocyte ballooning are indicated in Supplemental Figure 2. Steatosis severity was severe (score 3) and sustained after 9 weeks of feeding in both GAN and AMLN ob/ob-NASH mice. Both diets induced moderate-grade (score 2) lobular inflammation in almost all ob/ob mice without significant changes from

Statistical analyses
Except for RNA sequencing, data were analyzed using GraphPad Prism v7.03 software (GraphPad, La Jolla, CA, United States). All results are shown as mean ± standard error of mean. A two-way ANOVA with Tukey’s multiple comparisons test was performed for body weight and quantitative histological analyses. A one-way ANOVA with Dunnett’s post-hoc test was used for all other parameters. A \( P \) value < 0.05 was considered statistically significant.

Reactome pathway database\(^{[39]}\) was used as gene annotation in a gene set analysis using the R package PIANO v.1.18.1\(^{[38]}\), with the Stouffer method and Benjamini-Hochberg adjusted \( P \) values (FDR < 0.01).

Statistical analyses
Except for RNA sequencing, data were analyzed using GraphPad Prism v7.03 software (GraphPad, La Jolla, CA, United States). All results are shown as mean ± standard error of mean. A two-way ANOVA with Tukey’s multiple comparisons test was performed for body weight and quantitative histological analyses. A one-way ANOVA with Dunnett’s post-hoc test was used for all other parameters. A \( P \) value < 0.05 was considered statistically significant.
Table 1: Plasma and liver biomarkers in ob/ob mice fed amylin liver non-alcoholic steatohepatitis (AMLN) or Gubra amylin non-alcoholic steatohepatitis (GAN) diet for 8-16 wk

| Group         | Weeks on diet | n  | ALT (U/L) | Plasma TG (mmol/L) | Plasma TC (mmol/L) | Liver lipid mass (% of liver weight) |
|---------------|---------------|----|-----------|--------------------|-------------------|-------------------------------------|
| Chow C57      | 8             | 6  | 115 ± 60  | 192 ± 77           | 1.7 ± 0.2         | 3.8 ± 0.2                           |
|               | 12            | 6  | 67 ± 10   | 93 ± 16            | 1.7 ± 0.1         | 3.5 ± 0.1                           |
|               | 16            | 6  | 61 ± 18   | 82 ± 18            | 2.2 ± 0.2         | 3.8 ± 0.3                           |
| GAN ob/ob     | 8             | 4  | 913 ± 113  | 663 ± 37          | 1.2 ± 0.2        | 11.8 ± 0.9                           |
|               | 12            | 5  | 959 ± 93  | 660 ± 52           | 1.4 ± 0.1        | 12.4 ± 1.3                           |
|               | 16            | 6  | 868 ± 102  | 674 ± 25       | 1.5 ± 0.2        | 14.3 ± 0.8                           |
| AMLN ob/ob    | 16            | 6  | 654 ± 39  | 399 ± 23           | 1.0 ± 0.1        | 11.0 ± 0.4                           |

*a* < 0.05 vs corresponding feeding period in Chow-fed C57BL/6j (Chow C57) mice,
*a* < 0.05 vs corresponding feeding period in amylin liver non-alcoholic steatohepatitis (AMLN) ob/ob mice. TC: Total cholesterol; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TG: Total triglycerides; AMLN: Amylin liver non-alcoholic steatohepatitis diet; GAN: Gubra amylin liver steatohepatitis (GAN) diet for 8-16 wk mice. Feeding week 9 to 16. The rate of hepatocyte ballooning was low in ob/ob mice fed the GAN or AMLN diet for 9 weeks, however, increased during the remainder of the feeding period. Hepatocyte ballooning did not progress beyond grade 1 in ob/ob mice. Terminal quantitative histopathological changes were also similar in ob/ob mice fed the GAN or AMLN diet, as indicated by morphomeric analyses of steatosis, inflammation and Col1a1 (Figure 3).

Liver transcriptome changes in ob/ob mice fed AMLN or GAN diet for 16 wk

To characterize the effect of 16-week feeding on global liver gene expression, the transcriptome of GAN and AMLN ob/ob-NASH mice vs. chow-fed C57 mice were analyzed by RNA sequencing. To assess the overall similarity of the individual transcriptome samples, a principal component analysis (PCA) was performed. The primary PCA, accounting for the major variability in the data set, yielded conspicuous clustering of transcriptome samples from GAN and AMLN ob/ob-NASH mice, being clearly separated from chow-fed C57 controls (Figure 4A), indicating that the two NASH-promoting diets overall promoted substantial, however highly similar, alterations in liver global gene signatures of ob/ob mice. In accordance, a total pool of 9725 and 9760 differentially expressed genes (DEGs) were identified in GAN and AMLN ob/ob-NASH mice, respectively, with virtually all regulated genes being shared in the two ob/ob-NASH groups (Figure 4B). For initial evaluation of the DEGs identified, we probed for candidate gene transcripts associated with NASH and fibrosis (see Supplemental Table 1). GAN and AMLN ob/ob-NASH mice showed significant and overlapping regulations of candidate genes (Figure 4C), particularly associated to modulated fatty acid synthesis (Fasn, Scd1), reduced fatty acid β-oxidation (Cpt-1), lowered triglyceride synthesis (Gpat4), reduced cholesterol synthesis (Hmgcr, Hmgs1) and transport (ApoCIII, Ldlr, Lrp1, Scarb1); impaired insulin (Akt, Irs1, Irs2) and FXR (Cyp7a1, Cyp8b1, Ostb) signaling; enhanced monocyte differentiation/recruitment (Ccr1, Ccr2, Cd14, Cd68, Cx3c1f, Il1a, Il1b, Mac-2, Mcp-1), pro-inflammatory signaling (NfkB, P38, Tgfb1, Tnfα); inflammasome (Ipf1, Nlrp1b, Nlrp3, Tlr4) and pro-apoptotic activity (Cas-p-8, Rip-1, Rip-3), and enhanced extracellular matrix (ECM) reorganization (a-Sma, Col1a1, Col1a2, Col3a1, Col5a1/2/3, Col6a1/2/3, Mmp2, Mmp13, Timp1/2/3). When performing a group-wise comparison of global gene expression profiles in GAN vs. AMLN ob/ob mice, liver transcriptome signatures were distinguished by only nine DEGs (Ces3b, Cfr1, Cyp1a1, Cyp2f2, Gm4788, Kegl, Serpina3k, Ugt1a9, Ugt2a3). To obtain further resolution of the liver transcriptome changes in GAN and AMLN ob/ob-NASH mice vs. chow-fed C57 controls, a gene set enrichment analysis was subsequently conducted. The Reactome gene annotation analysis identified several disease-relevant biological pathways significantly enriched in both GAN and AMLN ob/ob-NASH mice. Notably, all significantly enriched pathways were completely overlapping between GAN and AMLN ob/ob-NASH mice (Figure 4D).

Liver histopathology in C57 mice fed GAN or AMLN diet for 28 wk

To investigate liver histological changes in wild-type mice, C57 mice were fed chow (n = 15), GAN (n = 30) or AMLN (n = 30) diet for 28 wk. Histopathological scores and proportionate area of Col1a1 are shown in Figure 5. GAN and AMLN diets were both highly obesogenic in C57 mice. GAN DIO-NASH mice showed significantly higher
Figure 1  Metabolic parameters in ob/ob mice fed amylin liver non-alcoholic steatohepatitis (AMLN) or Gubra amylin non-alcoholic steatohepatitis (GAN) diet for 8-16 wk. A: Body weight; B: Body composition; C: Terminal liver weight (week 16); D: An intraperitoneal glucose tolerance test (ipGTT) was performed in week 7 of the feeding period, glucose excursion curves; E: Glucose area under the curve (AUC, 0-180 min); F: Plasma insulin (0, 15, 30 min). *P < 0.05, **P < 0.01, ***P < 0.001 vs chow-fed C57BL/6J (Chow C57) controls; ****P < 0.001 vs amylin liver non-alcoholic steatohepatitis (AMLN) diet (n = 5-6 mice per group). AMLN: Amylin liver non-alcoholic steatohepatitis diet; GAN: Gubra amylin non-alcoholic steatohepatitis diet; ipGTT: Intraperitoneal glucose tolerance test.

Endpoint body weight (46.0 ± 0.8 g) compared to AMLN DIO-NASH (40.6 ± 0.6 g, P < 0.001) and chow-fed C57 mice (30.7 ± 0.4 g, P < 0.001 vs GAN DIO-NASH and AMLN-DIO NASH mice). While age-matched chow-fed C57 mice displayed normal liver histology, GAN DIO-NASH mice developed severe steatosis (score 3, 30/30 mice) and moderate-to-severe lobular inflammation (score 0, 1/30 mice; score 1, 3/30 mice; score 2, 19/30 mice; score 3, 7/30 mice) upon 28 wk of feeding (Figure 5A and B). Hepatocyte ballooning was largely absent in GAN DIO-NASH mice (score 0, 26/30 mice; score 1, 4/30 mice, Figure 5C). Generally, a NAS of 5-6 was observed in GAN DIO-NASH mice (score 3, 1/30 mice; score 4, 3/30 mice; score 5, 17/30 mice; score 6, 7/30 mice; score 7, 2/30 mice, Figure 5D). Fibrosis was typically mild to moderate in GAN DIO-NASH mice (F0, 1/30 mice; F1, 10/30 mice; F2, 18/30 mice; F3, 1/30 mice), see Figure 5E. AMLN DIO-NASH mice showed a liver histological phenotype very similar to GAN DIO-NASH mice, as indicated by severe steatosis (score 3, 30/30 mice), moderate to severe lobular inflammation (score 0, 1/30 mice; score 1, 3/30 mice; score 2, 19/30 mice; score 3, 7/30 mice), inconsistent hepatocyte ballooning (score 0, 17/30 mice; score 1, 13/30 mice), and mild-to-moderate fibrosis (F0, 3/30 mice; F1, 4/30 mice; F2, 23/30 mice; F3, 0/30 mice). In addition, Col1a1 proportionate areas were increased to a similar degree in GAN and AMLN DIO-NASH mice, as
Figure 2 Liver biopsy-confirmed non-alcoholic fatty liver disease activity score and fibrosis scores in ob/ob mice fed amylin liver non-alcoholic steatohepatitis (AMLN) or Gubra amylin non-alcoholic steatohepatitis (GAN) diet for 16 wk. A: Representative images of terminal liver morphology (upper panel: hematoxylin-eosin staining, lower panel: Picro-Sirus red staining, 20× magnification, scale bar 100 µm); B: Number of animals with higher, same or lower post-biopsy histopathology score compared to corresponding pre-biopsy score (n = 8-10 mice per group). Left panel: Non-alcoholic fatty liver disease activity score (NAS); right panel: Fibrosis score; C: Individual pre-biopsy and terminal NAS and fibrosis scores. AMLN: Amylin liver non-alcoholic steatohepatitis diet; GAN: Gubra amylin non-alcoholic steatohepatitis diet; NAFLD: Non-alcoholic fatty liver disease; NAS: Non-alcoholic fatty liver disease activity score.

compared to chow-fed C57 mice, see Figure 5F.

DISCUSSION

The AMLN DIO-NASH and ob/ob-NASH mouse models have been extensively validated and characterized in an increasing number of pharmacology studies. Here, we compared the metabolic and liver histological phenotype in ob/ob mice fed the AMLN diet or a modified AMLN diet (GAN diet) with Primex shortening, a trans-fat containing food additive, substituted with equivalent amounts of palm oil. The GAN and AMLN diets promoted similar biopsy-confirmed liver lesions with hallmarks of fibrotic NASH in both ob/ob and C57 mice. Hence, the maintained NASH phenotype in both ob/ob and C57 mice indicates the utility of GAN DIO mouse models of biopsy-confirmed NASH for the preclinical characterization of novel drug therapies for NASH.

The composition of the AMLN diet, containing high levels of saturated fat, fructose, trans-fat and cholesterol, reflects dietary factors considered important in the pathogenesis of NAFLD/NASH. Accordingly, excess energy intake from dietary fat and simple sugars (Western diets) has been strongly linked to NAFLD/NASH[41,42]. In particular, increased consumption of saturated fats and fructose has been associated with the deleterious effects of intrahepatoc cellular lipid accumulation, enhanced lipogenesis, insulin resistance, hepatocyte oxidative stress and inflammation in NAFLD/NASH[43-47]. Although less well-characterized in NASH, trans-unsaturated fat consumption and dietary cholesterol may sensitize to the hepatotoxic effects of...
Figure 3 Quantitative histopathological changes in ob/ob mice fed amylin liver non-alcoholic steatohepatitis (AMLN) or Gubra amylin non-alcoholic steatohepatitis (GAN) diet for 16 wk. Fractional (%) area of steatosis (hematoxylin-eosin staining), inflammation [galectin-3 immunostaining and fibrosis (collagen-1a1) immunostaining] determined by imaging-based morphometry (n = 8-10 mice per group). A: Steatosis; Galectin-3; C: Collagen-1a1. Scale bar 100 µm. AMLN: Amylin liver non-alcoholic steatohepatitis diet; GAN: Gubra amylin non-alcoholic steatohepatitis diet; Col1a1: Collagen-1a1.

excessive fat and fructose intake\textsuperscript{[31,32,48,49]}. Because the FDA has recently imposed a ban on the use of trans-fat additives in foods, this prompted us to develop a compatible mouse model of NASH based on an obesogenic diet high in saturated fat and with a nutrient composition and caloric density similar to the AMLN diet.

The GAN and AMLN diets were both highly obesogenic in ob/ob mice. Notably, weight gain and adiposity were even more pronounced in mice fed the GAN diet. Other high-fat/trans-fat diets have been reported inducing slightly less weight gain in wild-type mice compared to trans-fat-free hypercaloric diets\textsuperscript{[36]}. Although not specifically addressed in the present study, it may be speculated that substitution of trans-fat with palm oil led to improved diet palatability and/or fat absorption rates. This is also indirectly supported by the observation that hyperphagic ob/ob mice fed the AMLN diet attain slightly less weight gain compared to chow feeding\textsuperscript{[22,23]}. Consistent with previous reports\textsuperscript{[22,24,27]}, the AMLN diet did not influence glucose homeostasis in ob/ob mice which contrasts findings of mild glucose intolerance in obese wild-type mice fed other high-fat/trans-fat diet types\textsuperscript{[31,32,50]}. The AMLN diet has been reported to elevate endogenous glucose production in C57 mice\textsuperscript{[51]}, suggesting development of peripheral insulin resistance. As also C57 mice fed the AMLN diet...
Figure 4  Liver transcriptome changes in ob/ob mice fed amylin liver non-alcoholic steatohepatitis (AMLN) or Gubra amylin non-alcoholic steatohepatitis (GAN) diet for 16 wk. Overview of hepatic gene expression profiles in ob/ob mice fed amylin liver non-alcoholic steatohepatitis (AMLN) or Gubra amylin non-alcoholic steatohepatitis (GAN) diet compared to age-matched chow-fed ob/ob mice (n = 8-10 mice per group). A: Principal component analysis of samples based on top 500 most variable gene expression levels; B: Group-wise comparison of total number of differentially expressed genes (false discovery rate < 0.05) between ob/ob mice fed AMLN or GAN diet for 16 wk vs chow-fed C57BL/6J (Chow C57) mice; C: Relative gene expression levels (z-scores) of differentially regulated candidate genes associated with NASH and fibrosis. In-house gene panel on candidate genes is indicated in Supplemental Table 1; D: Group-wise comparison of global liver transcriptome changes according to enrichment of individual gene sets in the Reactome pathway database. Regulated pathways are ranked according to level of statistical significance (P value). AMLN: Amylin liver non-alcoholic steatohepatitis diet; GAN: Gubra amylin non-alcoholic steatohepatitis diet; NASH: Non-alcoholic steatohepatitis.
Figure 5 Liver histopathological scores and collagen 1a1 deposition in C57BL/6J mice fed chow, amylin liver non-alcoholic steatohepatitis (AMLN) or Gubra amylin non-alcoholic steatohepatitis (GAN) diet for 28 wk. A: Steatosis; B: Lobular inflammation; C: Hepatocyte ballooning; D: Non-alcoholic fatty liver disease activity score (NAS); E: Fibrosis score; F: Collagen-1a1 fractional area (mean ± SEM). *P < 0.001 vs chow-fed C57BL/6J (Chow C57) mice. AMLN: Amylin liver non-alcoholic steatohepatitis diet; GAN: Gubra amylin non-alcoholic steatohepatitis diet; NASH: Non-alcoholic steatohepatitis.

Consistent with the obese phenotype in GAN and AMLN ob/ob-NASH mice, the two models demonstrated pronounced hepatomegaly and intrahepatic lipid accumulation. Development of hypercholesterolemia, but not hypertriglyceridemia, was also a shared feature in GAN and AMLN ob/ob-NASH mice, possibly attributed to suppressed hepatic triglyceride secretion, as high dietary cholesterol intake can downregulate hepatic cholesterol ester and lipoprotein synthesis. This is supported by our finding of reduced expression of several hepatic genes involved in cholesterol synthesis and transport. Enhanced hepatic fat uptake combined with
impaired capacity to secrete fatty acids may thus be important mechanisms leading to marked steatosis in GAN and AMLN ob/ob mice. Hepatic injury was suggested by increased levels of plasma transaminases in GAN and AMLN ob/ob mice, subsequently confirmed by liver histology. We have previously reported that ob/ob mice develop reliably manifest NASH when maintained on AMLN diet for a relatively short feeding period (≥ 12 wk). The AMLN ob/ob-NASH model is characterized by biopsy-confirmed severe hepatic steatosis, moderate to severe lobular inflammation, mild hepatocyte ballooning and fibrotic lesions increasing in severity with prolonged feeding periods[23-25], recapitulating clinical histopathological criteria for the diagnosis of fibrosing NASH[25]. Also, the AMLN ob/ob-NASH model has been extensively characterized in pharmacology studies[25-27]. Notably, ob/ob mice fed the GAN and AMLN diet, respectively, developed a highly similar fibrotic NASH phenotype with comparable within-subject disease progression rates during the feeding period. Accordingly, GAN and AMLN-ob/ob-NASH mice demonstrated similar liver histopathology, as determined by both standard clinical histopathological scoring and imaging-based quantitative histological assessment of steatosis, inflammation and fibrosis.

The GAN and AMLN diets induced virtually identical hepatic transcriptome signatures with marked alterations in candidate genes associated with NAFLD/NASH. An unsupervised analysis for full-scale mapping and functional annotation of liver transcriptome signatures confirmed completely overlapping GAN and AMLN diet-induced hepatic signaling pathway perturbations with signatures of inefficient intrahepatic lipid and carbohydrate handling, stimulated immune cell activity, increased apoptotic activity, ECM remodeling and cell cycle modulation. In addition to suppressed transcription of genes associated with cholesterol metabolism (discussed above), a subset of genes involved in fatty acid catabolism (β-oxidation) and storage (triglyceride synthesis) were also downregulated. This could indirectly suggest free fatty acid overload and defective lipid compartmentation, which has been associated with hepatocyte cytotoxicity (lipotoxicity), inflammation and apoptosis in NASH[20-22]. Also, increased immune activity and hepatocyte damage was supported by upregulation of genes involved in monocyte differentiation /recruitment, pro-inflammatory cytokine production, inflammasome activation and pro-apoptotic signaling. The significant upregulation of a-Sma, multiple collagen isoforms (Col1a1, Col1a2, Col3a1, Col5a1/2/3, Col6a1/2/3) and molecules involved in ECM reorganization (Mmp2, Mmp13, Timp1/2/3), suggests that hepatic collagen accumulation in GAN and AMLN ob/ob-NASH mice is a combined effect of stimulated fibrogenesis and altered balance between the activity of collagen-degrading matrix metalloproteinases and tissue inhibitors of metalloproteinases.

The observation that the GAN and AMLN diets both promoted consistent fibrotic NASH in ob/ob mice indicates that palm oil supplementation fully compensated for the lack of trans-fat in the GAN diet. The extent of hepatic saturated fatty acid accumulation parallels disease severity in NAFLD/NASH patients[23], and inefficient disposal of saturated free fatty acids is considered hepatotoxic[6,40]. Specifically, the particularly high levels of palmitic acid in the GAN diet (37% of total fat by weight) compared to the AMLN diet (17% of total fat by weight) invites the possibility that this nutritional component played an integral role in the development and progression of liver pathology in GAN ob/ob-NASH mice. In support of this view, high palmitic acid (palmitate at physiological pH) levels in hepatocytes and non-parenchymal liver cells can trigger substantial lipotoxic damage through various mechanism associated with NASH pathology, including oxidative stress[44], endoplasmic reticulum stress[45], pro-apoptotic signaling[46] as well as Kupffer cell[47] and hepatic stellate cell activation[48]. In addition to direct cytotoxicity, hepatic palmitic acid overload can also promote hepatotoxic effects via increased formation palmitate-derived complex lipids, including ceramides[49]. Interestingly, long-term AMLN diet feeding has been reported to elevate hepatic levels of palmitate-containing ceramides in C57 mice, most likely due to incomplete mitochondrial fatty acid oxidisation nutritional as result of nutritional overload[20]. Compared to AMLN ob/ob-NASH mice, longer AMLN diet feeding periods (≥ 26 wk) are required for inducing consistent fibrotic NASH in C57 mice[49,50,51], which is likely explained by hyperphagia-driven excessive AMLN diet intake in leptin-deficient ob/ob-NASH mice. A comparative study was therefore also performed in C57 mice fed the GAN or AMLN diet for 28 wk (DIO-NASH mice). Similar to ob/ob mice, C57 mice showed significantly greater weight gain when fed the GAN diet compared to AMLN diet. Histological assessments of biopsied liver specimens revealed highly compatible liver lesions in GAN and AMLN DIO-NASH mice. Both models presented with manifest NASH (NAS ≥ 4), characterized by severe steatosis and moderate-to-severe lobular inflammation. In GAN DIO-NASH mice, fibrosis stage was mild to moderate with significantly increased proportionate area of Col1a1 compared to...
Boland ML et al. Translational mouse model of non-alcoholic steatohepatitis

ARTICLE HIGHLIGHTS

Research background
Non-alcoholic steatohepatitis (NASH) is an obesity-associated liver disease with marked unmet medical need. Various diet-induced obese animal models of NASH have been employed in preclinical research, target discovery and drug development. The trans-fat containing aminyl liver NASH (AMLN) diet, high in fat, fructose and cholesterol, has been widely used in ob/ob and C57BL/6J mice for reliably inducing metabolic and liver histopathological changes recapitulating hallmarks of NASH.

Research motivation
A recent ban on trans-fats as food additive has prompted the development of a trans-fat free high-fat diet capable of promoting a compatible level of disease in ob/ob and C57BL/6J mice.

Research objectives
The present study aimed to develop and characterize a liver biopsy-confirmed obese mouse model of NASH based on an isocaloric palmitic acid-enriched diet with a nutrient composition similar to the AMLN diet.

Research methods
Male ob/ob mice were fed AMLN diet or a modified AMLN diet with trans-fat (Primex

ob/ob mice were fed AMLN diet or a modified AMLN diet with trans-fat (Primex

ob/ob mice were fed AMLN diet or a modified AMLN diet with trans-fat (Primex

ob/ob mice were fed AMLN diet or a modified AMLN diet with trans-fat (Primex

ob/ob mice were fed AMLN diet or a modified AMLN diet with trans-fat (Primex
shortening) substituted by equivalent amounts of palm oil [Gubra Amylin NASH (GAN) diet] for 8, 12 and 16 wk. In addition, C57BL/6J mice were fed AMLN or GAN diet for 28 wk. AMLN and GAN diets were isocaloric (40% fat kcal; 10% sucrose, 22% fructose, 2% cholesterol). Disease phenotyping included metabolic, liver biochemical/histopathological/transcriptomics as well as gut microbiome analyses.

Research results

In ob/ob mice, the GAN diet was more obesogenic and adipogenic compared to the AMLN diet. Whereas the GAN diet promoted impaired oral glucose tolerance in ob/ob mice, the AMLN diet had no effect on glucose regulation. The GAN and AMLN diets induced similar severity of liver biopsy-confirmed steatosis, lobular inflammation, hepatocyte ballooning and fibrotic lesions. In addition, hepatic transcriptome and gut microbiome changes were similar in ob/ob mice fed the GAN and AMLN diet. Also, C57BL/6J mice fed the GAN and AMLN developed a similar histological phenotype of mild to moderate fibrotic NASH.

Research conclusions

Substitution of trans-fat (Primex in the AMLN diet) with saturated fat (palm oil in the GAN diet) for preclinical characterization of novel NASH treatments.

Research perspectives

GAN diet-based ob/ob and C57Bl/6J mouse models of biopsy-confirmed NASH are applicable ob/ob and C57BL/6J mouse models of biopsy-confirmed NASH are applicable to discovery research perspectives.

ACKNOWLEDGEMENTS

The authors would like to acknowledge Benji Gill, Stephanie Oldham (MedImmune, Gaithersburg, MD), Mikkel Christensen-Dalsgaard and Lillian Petersen (Gubra) for skillful technical assistance.

REFERENCES

1. Bedossa P. Current histological classification of NAFLD: Strength and limitations. Hepatol Int 2013; 7 Suppl 2: 765-770. PMID: 26202292 DOI: 10.1007/s12027-013-9446-2

2. Angulo P, Keach JC, Watts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362. PMID: 10573511 DOI: 10.1002/hep.510300604

3. Ratzin V, Giral P, Charlotte F, Brukert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Pouyart N. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123. PMID: 10833486 DOI: 10.1016/S0016-5085(00)70364-7

4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84. PMID: 26707365 DOI: 10.1002/hep.28431

5. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017; 14: 32-42. PMID: 27729660 DOI: 10.1038/nrgastro.2016.147

6. Bedossa P. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. Liver Int 2018; 38 Suppl 1: 64-66. PMID: 29427497 DOI: 10.1111/liv.13653

7. Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int 2017; 37 Suppl 1: 85-89. PMID: 28052629 DOI: 10.1111/lit.13301

8. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Ansee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol 2015; 62: 1148-1155. PMID: 25477264 DOI: 10.1016/j.jhep.2014.11.034

9. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-54.e1-9. quiz e39-40. PMID: 24768810 DOI: 10.1016/j.cgh.2014.04.014

10. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrrel LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321. PMID: 15915861 DOI: 10.1002/hep.20701

11. Rosso N, Chavez-Tapia NC, Tibirelli C, Bellentani S. Translational approaches: From fatty liver to nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20: 9038-9049. PMID: 25083077 DOI: 10.3748/wjg.v20.i27.9038

12. Berlanga A, Guita-Jurado E, Porras JA, Auguste T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 2014; 7: 221-239. PMID: 25045276 DOI: 10.2147/CEG.S62831

13. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2017; 14: 397-411. PMID: 28457345 DOI: 10.1038/nrgastro.2017.39

14. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 2015; 14: 908-922. PMID: 25967350 DOI: 10.1038/nrgastro.2015.94

15. Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 2015; 12: 387-400. PMID: 26055245 DOI: 10.1038/nrgastro.2015.54

16. Hansen HH, Feigh M, Veidal SS, Riboldt KT, Vrang N, Fosgerau K. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today 2017; 22: 1707-1718. PMID: 28687495 DOI: 10.1016/j.drudis.2017.06.007
STAR: Ultrafast universal RNA-seq aligner. Bioinformatics, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR.

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 2013; 29: 15-21 [PMID: 23048866 DOI: 10.1093/bioinformatics/bts635]
Fahregat A, Jupe S, Matthews L, Sidirooulos K, Gillespie M, Garapati P, Haw R, Jassal B, Kornfinger F, May B, Milic M, Roca CD, Rothfels K, Sevilla C, Shamovský V, Shorser S, Varusai T, Viteri G, Weisser J, Wu G, Stein L, Hernjakob H, D'Eustachio P. The Reactome Pathway Knowledgebase. *Nucleic Acids Res* 2018; 46:D649-D655 [PMID: 29145629 DOI: 10.1093/nar/gkx1132]

Väremo L, Nielsen J, Noookaev I. Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods. *Nucleic Acids Res* 2013; 41:4378-4391 [PMID: 23444143 DOI: 10.1093/nar/gkt111]

Oddy WH, Herbison CE, Jacoby P, Ambrosius GL, O'Sullivan TA, Ayonrinde OT, Olynuk JK, Black LJ, Beilin LJ, Mori TA, Hands BP, Adams LA. The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. *Am J Gastroenterol* 2013; 108:778-785 [PMID: 23545714 DOI: 10.1038/ajg.2013.95]

Asrhi M, Jornayvaz FR. Diets and nonalcoholic fatty liver disease: The good and the bad. *Clin Nutr* 2014; 33:186-190 [PMID: 24262589 DOI: 10.1016/j.clnu.2013.11.003]

Lim JS, Muets-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. *Nat Rev Gastroenterol Hepatol* 2010; 7:251-264 [PMID: 20368739 DOI: 10.1038/nrgastro.2010.41]

Alkhoury N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: Not all lipids are created equal. *Expert Rev Gastroenterol Hepatol* 2009; 3:445-451 [PMID: 19673611 DOI: 10.1586/egh.09.32]

Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM. Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. *Hepatology* 2010; 51:1961-1971 [PMID: 20301112 DOI: 10.1002/hep.23535]

Moore JB, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. *Nutrients* 2014; 6:5679-5703 [PMID: 25514388 DOI: 10.3390/nu61215679]

Della Pepa G, Vetrai C, Lombardi G, Bozzetto L, Ammatti G, Rivellese AA. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals. *Nutrients* 2017; 9 [pii]: E1065 [PMID: 28954437 DOI: 10.3390/nu91101065]

Walenbergh SM, Shiri-Sverdlov R. Cholesterol is a significant risk factor for non-alcoholic steatohepatitis. *Expert Rev Gastroenterol Hepatol* 2015; 9:1334-1346 [PMID: 26395315 DOI: 10.1586/17474124.2015.1092382]

Jeyapal S, Patcha UK, Mullapudi VS, Ghosh S, Sakamuri A, Kona SR, Vadakattu SS, Madakasa C, Ibrahim A. Chronic consumption of fructose in combination with trans fatty acids but not with saturated fatty acids induces nonalcoholic steatohepatitis with fibrosis in rats. *Eur J Nutr* 2018; 57:2171-2187 [PMID: 28676973 DOI: 10.1007/s00394-017-1492-1]

Zhao X, Shen C, Zha H, Wang C, Liu X, Sun H, Han S, Wang P, Deng Z, Ma X, Hu K, Sun A, Ge J. Trans-Fatty Acids Aggravate Obesity, Insulin Resistance and Hepatic Steatosis in C57BL/6 Mice. Possibly by Suppressing the IRS1 Dependent Pathway. *Molecules* 2016; 21: pii: E705 [PMID: 27248994 DOI: 10.3390/molecules21060705]

Kalavsalapalli S, Bri F, Guingab J, Vergraaf A, Garrett TJ, Sunny NF, Cusi K. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. *J Endocrinol* 2019; 241:293-305 [PMID: 31082799 DOI: 10.1530/JOE-19-00203]

Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, Collugh AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. *Am J Med* 1999; 107:450-455 [PMID: 10569299 DOI: 10.1016/S0002-9343(99)00271-5]

Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM. Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. *Hepatology* 2012; 56:943-951 [PMID: 22505194 DOI: 10.1002/hep.25772]

Williams CD, Stengel J, Ashke MJ, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. *Gastroenterology* 2011; 140:124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]

Haluzik M, Colombo C, Gavrilova O, Chua S, Wolf N, Chen M, Stannard B, Dietz KR, Le Roith D, Haluzik M. Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. *J Endocrinol* 2004; 205:293-305 [PMID: 15059949 DOI: 10.1210/en.2004-00219]

Grefohorst A, van Dijk TH, Hammer A, van der Sluijs FH, Havinga R, Havekes LM, Romijn JA, Groot PH, Reitman ML. Genetic background (C57BL/6J versus FVB/N) strongly influences the severity in patients with nonalcoholic fatty liver disease. *Eur J Endocrinol* 2015; 172:943-951 [PMID: 22505194 DOI: 10.1002/hep.25772]

Beilin LJ, Mori TA, Adams LA. Consumption of fructose in combination with trans fatty acids but not with saturated fatty acids induces nonalcoholic steatohepatitis with fibrosis in rats. *Eur J Nutr* 2018; 57:2171-2187 [PMID: 28676973 DOI: 10.1007/s00394-017-1492-1]

Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM. Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. *Hepatology* 2012; 56:943-951 [PMID: 22505194 DOI: 10.1002/hep.25772]
Bertrand-Michel J, Brunelle A, Guettier C, Le Naour F. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients. Sci Rep 2017; 7: 46658 [PMID: 28436449 DOI: 10.1038/srep46658]

64 Moto M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and gluotoxicity in nonalcoholic fatty liver disease. Metabolism 2016; 65: 1049-1061 [PMID: 26997538 DOI: 10.1016/j.metabol.2016.02.014]

65 Liangpunsakul S, Chalasani N. Lipid mediators of liver injury in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2019; 316: G75-G81 [PMID: 30383414 DOI: 10.1152/ajpgi.00170.2018]

66 Zhang K, Kim H, Fu Z, Qiu Y, Yang Z, Wang J, Zhang D, Tong X, Yin L, Li J, Wu J, Qi NR, Houten SM, Zhang R. Deficiency of the Mitochondrial NAD Kinase Causes Stress-Induced Hepatotoxicity in Mice. Gastroenterology 2018; 154: 224-237 [PMID: 28923496 DOI: 10.1053/j.gastro.2017.09.010]

67 Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 2006; 291: E275-E281 [PMID: 16492868 DOI: 10.1152/ajpendo.00644.2005]

68 Cazanave SC, Mott JL, Bronk SF, Werneberg NW, Fingsad CS, Meng XW, Finnberg N, El-Deiry WS, Kaufmann SH, Gores GJ. Death receptor 5 signaling promotes hepatocyte lipopoptosis. J Biol Chem 2011; 286: 39336-39348 [PMID: 21914093 DOI: 10.1074/jbc.M111.230420]

69 Luo W, Xu Q, Wang Q, Wu H, Jia J. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep 2017; 7: 44612 [PMID: 28300213 DOI: 10.1038/srep44612]

70 Hetherington AM, Sawyer CG, Zilberman E, Stoianov AM, Robson DL, Borradale NM. Differential Lipotoxic Effects of Palmitate and Oleate in Activated Human Hepatic Stellate Cells and Epithelial Hepatoma Cells. Cell Physiol Biochem 2016; 39: 16-48 [PMID: 27269296 DOI: 10.1159/0004947866]

71 Hirsuova P, Ibrahim SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: Relevance to NASH pathogenesis. J Lipid Res 2016; 57: 1758-1770 [PMID: 27049024 DOI: 10.1194/jlr.R065357]

72 Honda Y, Imai K, Kato T, Kessoku T, Ogawa Y, Tomeno W, Kato S, Mawatari H, Fujita K, Oneda M, Saito S, Nakajima A. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS One 2016; 11: e0146337 [PMID: 26731267 DOI: 10.1371/journal.pone.0146337]

73 Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JJ. The effect of diet on the human gut microbiome: A metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009; 1: 6ra14 [PMID: 20368178 DOI: 10.1126/scitranslmed.3000322]

74 Zheng X, Huang F, Zhao A, Lei S, Zhang Y, Xie G, Chen T, Qu C, Rajani C, Dong B, Li D, Jia W. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. BMC Biol 2017; 15: 120 [PMID: 29241543 DOI: 10.1186/s12915-017-0462-7]

75 Frank DN, Bales ES, Monks J, Jackman MJ, MacLean PS, Ir D, Robertson CE, Orlicky DJ, McManaman JL. Perilipin-2 Modulates Lipid Absorption and Microbiome Responses in the Mouse Intestine. PLoS One 2015; 10: e0131944 [PMID: 26174095 DOI: 10.1371/journal.pone.0131944]

76 de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr 2018; 57: 861-876 [PMID: 28875318 DOI: 10.1007/s00394-017-1524-x]

77 Wong VW, Tse CH, Lam TT, Wong GL, Chiu AM, Chu WC, Yeung DK, Law PT, Kwan HS, Yu J, Sung JJ, Chan HL. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis—a longitudinal study. PLoS One 2013; 8: e62885 [PMID: 23638162 DOI: 10.1371/journal.pone.0062885]

78 Zhu L, Baker SS, Gill C, Liu A, Alkhoury R, Baker RD, Gill SR. Characterization of gut microbiomes of nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-609 [PMID: 23051555 DOI: 10.1002/hep.26093]

79 Boursier J, Mueller O, Barret M, Machado M, Fazanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hanaih G, Oberli F, Calle P, D shl AM. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016; 63: 764-775 [PMID: 26600078 DOI: 10.1002/hep.28556]

80 Da Silva HE, Teterina A, Comelli EM, Tavi B, Arendt BM, Fischer SE, Lou W, Allard JP. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep 2018; 8: 1466 [PMID: 29362454 DOI: 10.1038/s41598-018-19753-9]

81 El Kaoutari A, Armougom F, Gordon JJ, Raoul D, Henrissat B. The abundance and variety of carbohydrate-active enzymes in the human gut microbiota. Nat Rev Microbiol 2013; 11: 497-504 [PMID: 23748339 DOI: 10.1038/nrmicro3050]

82 Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell 2016; 165: 1332-1345 [PMID: 27259147 DOI: 10.1016/j.cell.2016.05.041]

83 Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JJ. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031 [PMID: 17183312 DOI: 10.1038/nature05414]

84 Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol 2016; 14: 20-32 [PMID: 26499895 DOI: 10.1038/nrmicro3552]

85 Miura K, Ohmishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 7381-7391 [PMID: 24966608 DOI: 10.3748/wjg.v20.i23.7381]

86 Derrrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microbiol Pathog 2017; 106: 171-181 [PMID: 28675998 DOI: 10.1016/j.micpath.2016.02.005]

87 Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hanady M, Chen YY, Knight R, Ahisma RS, Bushman F, Wu GD. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009; 137: 1716-24.e1-2 [PMID: 19706296 DOI: 10.1053/j.gastro.2009.08.042]
